Most recently, we showed that selectively inhibiting p38β MAPK using the kinase inhibitor nilotinib approved for chronic myelogenous leukemia alleviates muscle wasting in tumor-bearing mice (Sin et al., 2021). This evidence concerns the gene MAPK11 and neoplasm.